Soluble guanylyl cyclase activators—promising therapeutic option in the pharmacotherapy of heart failure and pulmonary hypertension

HIGHLIGHTS

• who: Grzegorz Grzeu015bk et al. from the Department Cardiology and Clinical Pharmacology, Faculty Health Sciences, Ludwik Rydygier Colle-gium Medicum in Bydgoszcz, Copernicus University, Ujejskiego St, Bydgoszcz, Poland have published the paper: Soluble Guanylyl Cyclase Activatorsu2014Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension, in the Journal: Molecules 2023, 861 of 27/07/2021
• what: The aim was to increase the activity of the enzyme and thus achieve a synergistic effect between the applied pharmacotherapy and the activation of guanylate cyclase .
• how: The randomized CAPACITY HFpEF trial was conducted in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.